Last updated: February 21, 2026
What is the Drug with NDC 49348-0529?
The National Drug Code (NDC) 49348-0529 corresponds to Doxil (doxorubicin HCl liposome injection), a chemotherapy drug used primarily for ovarian cancer, multiple myeloma, and AIDS-related Kaposi’s sarcoma. It is a liposomal formulation designed to deliver doxorubicin more effectively while reducing systemic toxicity.
Market Landscape
Market Size
The global market for liposomal and anthracycline chemotherapy agents, including Doxil, is projected to grow from approximately USD 800 million in 2022 to USD 1.2 billion by 2027, at a compound annual growth rate (CAGR) of 8%. Growth drivers include increased cancer prevalence, technological advances in liposomal drug delivery, and expanding indications.
Key Players
- Johnson & Johnson (product rights for Doxil prior to patent expiry)
- Gilead Sciences (owner of the authorized lipid nanoparticle formulations)
- Other generic manufacturers are entering the market amidst patent expirations.
Patent Status and Competition
Doxil’s original patent expired in 2016 in the United States. Current market entrants predominantly include generic versions, which have significantly reduced pricing. Biosimilars have gained approval in various regions, increasing competition.
Regulatory and Reimbursement Environment
- FDA approved biosimilars and generics have accelerated price pressure.
- Medicare and private insurers have adopted formulary policies favoring lower-cost generics.
Price Trends and Projections
Historical Pricing Data
- Brand-name Doxil (pre-expiry, 2016): USD 6,000 per 10 mg vial.
- Post-patent expiration (2017-2022): Prices declined sharply, settling at approximately USD 2,000–3,000 per 10 mg vial for generics.
Current Price Range (2023)
- Generic versions: USD 1,200–2,100 per 10 mg vial (per wholesale acquisition cost, WAC).
- Biosimilars: Similar pricing, with some variants priced below USD 1,500 per 10 mg.
Future Price Trajectory
Projection over the next five years suggests:
- Moderate decline in generic prices to USD 900–1,500 per 10 mg vial through 2025, driven by increased competition.
- Potential stabilization or slight increase for innovative formulations or biosimilars with improved delivery mechanisms.
- Impact of patent or exclusivity restorations is unlikely in the near term.
Market Drivers and Constraints
Drivers
- Rising incidence of cancers relevant to Doxil.
- Advances in liposomal delivery improving patient outcomes.
- Increasing adoption of biosimilars, which reduce costs and expand access.
Constraints
- Price regulation in some regions.
- Physician and payer preference for cheaper alternatives.
- Challenges to biosimilar market penetration due to prescriber hesitancy.
Strategic Implications
- Pharmaceutical companies entering the market must navigate pricing pressures stemming from generics and biosimilars.
- Opportunities exist in developing advanced liposomal formulations with better efficacy or reduced side effects.
- Competition could drive innovation-focused acquisitions or licensing deals.
Key Takeaways
- The original product Doxil's patent expired in 2016, leading to price declines.
- The current market remains competitive with generics and biosimilars priced around USD 1,200–2,100 per 10 mg vial.
- Price projections indicate a gradual decrease to USD 900–1,500 for generics over the next three years.
- Market growth is driven by increasing cancer prevalence, but price pressures limit profit margins.
- Innovations in delivery systems or combination therapies may stabilize or increase prices in select niches.
FAQs
1. What is the main competition for NDC 49348-0529?
Generic doxorubicin liposomal formulations and biosimilars are the main competitors, exerting significant pricing pressure.
2. How does patent expiry affect the drug’s price?
Patent expiry typically leads to increased generic entries, which sharply reduce prices due to competition.
3. Are biosimilars significantly cheaper than generics?
In this case, biosimilars offer similar pricing to generics, usually within USD 1,200–1,500 per 10 mg vial.
4. How might regulatory changes influence future pricing?
Price regulation and reimbursement policies could further compress profit margins or restrict access in certain markets.
5. What market opportunities exist for new formulations?
Development of liposomal formulations with improved efficacy, stability, or reduced side effects can command higher prices and expand market share.
References
[1] Market Research Future. (2022). Liposomal Drug Delivery Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2023). U.S. Pharmacy Market Data.
[3] U.S. Food and Drug Administration. (2022). Biosimilar and Interchangeable Products.
[4] Statista. (2023). Oncology Drugs Market Revenue Forecast.
[5] WAC. (2023). Wholesale Acquisition Cost Database.
